Wall Matthew B, Demetriou Lysia, Giribaldi Bruna, Roseman Leor, Ertl Natalie, Erritzoe David, Nutt David J, Carhart-Harris Robin L
Perceptive Inc. (formerly Invicro LLC), Hammersmith Hospital, London (Wall, Demetriou, Ertl); Department of Metabolism, Digestion, and Reproduction (Wall, Ertl) and Centre for Psychedelic Research, Division of Psychiatry, Department of Brain Sciences, Faculty of Medicine (Wall, Ertl, Giribaldi, Roseman, Erritzoe, Nutt, Carhart-Harris), Imperial College London; Nuffield Department of Women's and Reproductive Health, University of Oxford, Oxford, UK (Demetriou); Department of Neurology, University of California, San Francisco (Carhart-Harris).
Am J Psychiatry. 2025 May 7:appiajp20230751. doi: 10.1176/appi.ajp.20230751.
Psilocybin is an emerging intervention for depression that may be at least as effective as selective serotonin reuptake inhibitors (SSRIs), but effects of the two treatments on the neural correlates of emotional processing have never been directly compared.
The authors assessed neural responses to emotional faces using blood-oxygen-level-dependent (BOLD) functional MRI (fMRI) in two groups with major depression. One group (N=25; 9 women and 16 men) received two dosing sessions with 25 mg psilocybin plus 6 weeks of daily inert placebo, and the second group (N=21; 6 women and 15 men) received 6 weeks of escitalopram plus two dosing sessions with a nonpsychoactive (placebo) dose of 1 mg psilocybin. Both groups had equal psychological support throughout: 3 hours of preparation, one in-person integration session following the psilocybin dosing sessions, and two further integration sessions conducted via video call or telephone. An emotional face fMRI paradigm was completed before treatment and at the 6-week posttreatment primary end point (3 weeks following psilocybin dosing sessions).
Patient group (psilocybin versus escitalopram) interacted with time point (before versus after treatment) on a distributed set of cortical regions. Post hoc within-condition analyses showed that posttreatment BOLD responses to emotional faces of all types were significantly reduced in the escitalopram group, with no change or a slight increase in the psilocybin group. Analyses of amygdala responsivity showed a reduction of response to fearful faces in the escitalopram group, but lesser effects for the psilocybin group.
Despite large improvements in depressive symptoms in the psilocybin group, psilocybin therapy had only a minor effect on brain responsiveness to emotional stimuli. These results are consistent with prior findings that the antidepressant action of SSRIs is often accompanied by a reduction in emotional responsiveness, but this effect may not occur in psychedelic therapy.
裸盖菇素是一种新兴的抑郁症干预手段,其疗效可能至少与选择性5-羟色胺再摄取抑制剂(SSRI)相当,但这两种治疗方法对情绪加工神经关联的影响从未被直接比较过。
作者在两组重度抑郁症患者中,使用基于血氧水平依赖(BOLD)的功能磁共振成像(fMRI)评估对情绪面孔的神经反应。一组(N = 25;9名女性和16名男性)接受两次25毫克裸盖菇素给药疗程加6周每日惰性安慰剂,第二组(N = 21;6名女性和15名男性)接受6周艾司西酞普兰加两次1毫克非精神活性(安慰剂)剂量裸盖菇素给药疗程。两组在整个过程中都获得了同等的心理支持:3小时准备期、裸盖菇素给药疗程后的一次面对面整合期,以及通过视频通话或电话进行的另外两次整合期。在治疗前和治疗后6周的主要终点(裸盖菇素给药疗程后3周)完成情绪面孔fMRI范式。
患者组(裸盖菇素与艾司西酞普兰)与时间点(治疗前与治疗后)在一组分布的皮质区域存在交互作用。事后组内分析表明,艾司西酞普兰组治疗后对所有类型情绪面孔的BOLD反应显著降低,裸盖菇素组无变化或略有增加。杏仁核反应性分析表明,艾司西酞普兰组对恐惧面孔的反应降低,但裸盖菇素组影响较小。
尽管裸盖菇素组抑郁症状有大幅改善,但裸盖菇素疗法对大脑对情绪刺激的反应性仅有轻微影响。这些结果与先前的发现一致,即SSRI的抗抑郁作用通常伴随着情绪反应性降低,但这种效应在迷幻疗法中可能不会出现。